Author + information
- Received March 15, 2013
- Revision received June 5, 2013
- Accepted June 25, 2013
- Published online October 1, 2013.
- Mayank Yadav, MD∗,
- Tullio Palmerini, MD†,
- Adriano Caixeta, MD, PhD‡,
- Mahesh V. Madhavan, BA∗,
- Elias Sanidas, MD, PhD∗,
- Ajay J. Kirtane, MD, SM∗,
- Gregg W. Stone, MD∗ and
- Philippe Généreux, MD∗,§∗ ()
- ∗Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
- †Istituto di Cardiologia, University of Bologna, Bologna, Italy
- ‡Hospital Israelita Albert Einstein and Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
- §Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, Québec, Canada
- ↵∗Reprint requests and correspondence:
Dr. Philippe Généreux, Columbia University Medical Center and The Cardiovascular Research Foundation, 111 East 59th street, 12th Floor, New York, New York 10022.
The introduction of the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score has prompted a renewed interest for angiographic risk stratification in patients undergoing percutaneous coronary intervention. Syntax score is based on qualitative and quantitative characterization of coronary artery disease by including 11 angiographic variables that take into consideration lesion location and characteristics. Thus far, this score has been shown to be an effective tool to risk-stratify patients with complex coronary artery disease undergoing percutaneous coronary intervention in the landmark SYNTAX trial, as well as in other clinical settings. This review provides an overview of its current applications, including its integration with other nonangiographic clinical scores, and explores future applications of the SYNTAX and derived scores.
Dr. Palmerini has received speaking fees from Abbott Vascular. Mr. Madhavan has been supported by a grant from the Doris Duke Charitable Foundation to Columbia University that funds a clinical research fellowship. Dr. Stone has served as consultant for Abbott Vascular, Boston Scientific, Medtronic, and The Medicines Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received March 15, 2013.
- Revision received June 5, 2013.
- Accepted June 25, 2013.
- 2013 American College of Cardiology Foundation